T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.57% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.16% |
| 4 | Industrials | 12.02% |
| 5 | Technology | 10.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FRC
1551
DELISTED
First Republic Bank
FRC
| $2.43M | ﹤0.01% |
42,604
+8,534
| +25% | +$464K |
|
|
OCR
1552
DELISTED
OMNICARE INC
OCR
| $2.43M | ﹤0.01% |
31,506
+97
| +0.3% | +$7.37K |
|
1553
Liberty Media Series A
FWONA
$23.9B
| $2.42M | ﹤0.01% |
93,561
-615
| -0.7% | -$15.4K |
|
1554
HNI Corp
HNI
$3.53B
| $2.38M | ﹤0.01% |
43,080
-7,500
| -15% | -$385K |
|
|
BZC
1555
DELISTED
BREEZE-EASTERN CORPORATION COM
BZC
| $2.38M | ﹤0.01% |
230,868
-135,620
| -37% | -$1.36M |
|
1556
Trinity Industries
TRN
$2.36B
| $2.29M | ﹤0.01% |
89,490
+9,861
| +12% | +$216K |
|
1557
W.P. Carey
WPC
$16.3B
| $2.29M | ﹤0.01% |
34,357
+3,982
| +13% | +$274K |
|
1558
Everest Group
EG
$14.2B
| $2.28M | ﹤0.01% |
13,106
-124
| -0.9% | -$21.8K |
|
|
HGG
1559
DELISTED
hhgregg Inc.
HGG
| $2.26M | ﹤0.01% |
368,030
-36,220
| -9% | -$221K |
|
1560
Canadian National Railway
CNI
$76.7B
| $2.24M | ﹤0.01% |
33,520
+1,300
| +4% | +$88.5K |
|
1561
Wolfspeed
WOLF
$1.65B
| $2.23M | ﹤0.01% |
62,782
+2,367
| +4% | +$85.5K |
|
1562
Brookdale Senior Living
BKD
$3.02B
| $2.22M | ﹤0.01% |
58,704
+10,904
| +23% | +$399K |
|
1563
Arthur J. Gallagher & Co
AJG
$64.4B
| $2.19M | ﹤0.01% |
46,960
| – | – |
|
1564
Synopsys
SNPS
$80.7B
| $2.19M | ﹤0.01% |
47,368
+301
| +0.6% | +$13.5K |
|
1565
3D Systems Corp
DDD
$616M
| $2.16M | ﹤0.01% |
78,825
-6,300
| -7% | -$185K |
|
|
Y
1566
DELISTED
Alleghany Corp
Y
| $2.15M | ﹤0.01% |
4,426
| – | – |
|
1567
Theravance Biopharma
TBPH
$881M
| $2.15M | ﹤0.01% |
123,985
-218,963
| -64% | -$4.01M |
|
|
CBI
1568
DELISTED
Chicago Bridge & Iron Nv
CBI
| $2.14M | ﹤0.01% |
43,529
+2,482
| +6% | +$104K |
|
|
AMJ
1569
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
| $2.14M | ﹤0.01% |
+49,900
| New | +$2.2M |
|
1570
Crawford & Co Class B
CRD.B
$593M
| $2.12M | ﹤0.01% |
245,728
-6,700
| -3% | -$62.2K |
|
|
ASNA
1571
DELISTED
Ascena Retail Group, Inc.
ASNA
| $2.12M | ﹤0.01% |
7,312
-775
| -10% | -$196K |
|
|
BEAV
1572
DELISTED
B/E Aerospace Inc
BEAV
| $2.12M | ﹤0.01% |
33,258
| – | – |
|
|
SUNE
1573
DELISTED
SUNEDISON, INC COM
SUNE
| $2.11M | ﹤0.01% |
87,900
-664
| -0.7% | -$14.3K |
|
1574
UGI
UGI
$7.59B
| $2.09M | ﹤0.01% |
64,090
+6,850
| +12% | +$240K |
|
|
CYN
1575
DELISTED
CITY NATIONAL CORPORATION
CYN
| $2.09M | ﹤0.01% |
23,450
-2,000
| -8% | -$173K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.